Tag
compass pathways
- NRx Pharmaceuticals starts ketamine sales effort ahead of January shipments
- Compass Pathways reports completion of COMP360 psilocybin application
- Rapport Therapeutics reports US$815.4M liquidity and runway through 2029
- Compass Pathways reports US$444M cash and runway into 2028
- Definium Therapeutics reports 5.1‑point gap in second Phase 3 anxiety study
- FDA psychedelics hearing draws little pushback on future therapeutic use
- Small-scale Nature study shows psilocybin causes brain changes after one use
- Compass Pathways scores FDA priority voucher for synthetic psilocybin drug
- Psychedelic Therapeutics & Drug Development Conference kicks off in New Orleans
- African psilocybin cultivator 'Psyence' gets C$600K investment
- Investors flock to psychedelic start‑ups
- Compass Pathways, Hackensack Meridian Health collaborate on psilocybin treatment research
- American Medical Association approves medical code for psychedelic therapies coverage
- MindMed stock surges on Nasdaq listing approval
- Psilocybin treats depression as well as common antidepressant: study
- 2020's top 5 advancements in psychedelics